Early antithrombotic post-discharge therapy using prophylactic doac or dipyridamole improves long-term survival and cardiovascular outcomes in hospitalized covid-19 survivors

HIGHLIGHTS

• who: Lukas J. Motloch from the Queen Mary University of London, United Kingdom have published the paper: Early antithrombotic post-discharge therapy using prophylactic DOAC or dipyridamole improves long-term survival and cardiovascular outcomes in hospitalized COVID-19 survivors, in the Journal: (JOURNAL)
• what: This study has by design its limitations, mainly due to its single-center and retrospective design as well as lack of randomization and treatment arm blinding. Based on the study design, the authors were only able to analyze bleeding events requiring hospitalization, which is a major limitation of the study .
 



If you want to have access to all the content you need to log in!

Thanks :)

Username or E-mail:

If you don't have an account, you can create one here.